Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 14

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 14
---
 for purposes of complying with Nasdaq Listing Rule
5635(d), the issuance of the Series A Warrant Shares and certain provisions of the Series A Warrants, and (ii) approve a proposed amendment
to our amended and restated certificate of incorporation (the “Certificate of Incorporation”) to increase the total number
of shares of Common Stock authorized for issuance thereunder from 100,000,000 shares to 800,000,000 shares (the “Charter Amendment
Proposal”), at a special meeting of stockholders.

On March 7, 2025, the Company
also entered into a placement agency agreement with R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) as the sole placement
agent in connection with the Private Placement (the “Placement Agent”). As compensation to the Placement Agent, the Company
paid a commission equal to 7.0% of the aggregate gross proceeds from the Private Placement.

The Private Placement closed
on March 10, 2025. The Securities issued in the Private Placement were issued and offered pursuant to the exemptions from registration
provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.

Recent Developments

ATM Offering

On April 7, 2025, we entered
into Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) as sales agent, in
connection with an “at the market offering” under which we may offer and sell, from time to time in our sole discretion, shares
of our Common Stock having an aggregate offering price of up to $16,768,099 at market prices or as otherwise agreed with A.G.P. The compensation
to A.G.P. for sales of the shares is a placement fee of 3.0% of the gross sales price of the shares of Common Stock sold pursuant to the
Sales Agreement. In connection with entering into the Sales Agreement, on April 7, 2025, we filed with the SEC a prospectus supplement
relating to the offer, issuance and sale of up to $16,768,099 of our shares of Common Stock pursuant to the Sales Agreement. As of April
11, 2025, we have not sold any shares of Common Stock pursuant to the Sales Agreement.

<div align='center'>3</div>

Pursuant to the March 2025